Diabetic Macular Edema

Diabetic retinopathy can cause swelling of the center of the retina, the macula, and vision loss.

What is a Diabetic Macular Edema

Diabetic macular edema is swelling in the retina associated with diabetes. This swelling can blur and distort the vision. The swelling occurs because the walls of the small blood vessels are progressively more damaged in diabetes, and there is leakage of blood and fluid into the cells of the retina. There are a variety of options to treat diabetic macular edema. The oldest treatment is laser for retinal swelling. It has been studied for decades and has been shown to be safe and effective. As with all treatments, it is not curative, and it is not without risk, but laser is one of the safest things that we do in diabetic retinal care. Other newer treatments for diabetic retinal swelling have been shown to improve vision even more than laser in some cases, and have also been shown to be safe and effective in large modern trials. These treatments are a variety of injections given into the eye in the office, and they are sometimes given alone and sometimes given with laser in addition. There are two major classes of injections used in diabetic macular edema, and those are small molecule injections and corticosteroid injections. The injections work in different ways to reduce the leakage and swelling in the retina, and sometimes the different types of injections are both used. The injections are administered under local anesthesia, and are often relatively well-tolerated by patients. Injections are also amongst the safest procedures performed in the retinal clinic, and the specific risks and benefits of injections will be discussed by your doctor. Most patients with blurred vision from diabetic macular edema enjoy an improvement in vision with treatment. Often, treatment to maintain vision is ongoing, and the long-term treatment plan is individualized to each specific patient in our practice.

What is a Laser?

When diabetic macular edema is caused by focal areas of leakage, laser treatment can be helpful. Studies were done in the 1980's validating the use of laser to reduce the risk of vision loss and improve vision in patients with diabetic macular edema. The advantage of laser of intravitreal injections is that laser treatment usually only needs to be repeated a few times. Intravireal injections are given monthly. The disadvantage of laser, is that it does not improve vision as much as intravitreal injections do when the center of the macula is swollen. Many physicians will use both laser and intravitreal injections depending on the area of the macula that is swollen and the findings on examination and testing.

Lucentis for Diabetic Macular Edema

Monthly Lucentis therapy is helpful for patients with diabetic macular edema. With laser only, about 15 percent of patients have substantial visual improvement at 2 years. With Lucentis therapy, about 40 percent of patients have a substantial improvement in visual acuity. Subsequent studies have shown that ongoing monthly treatment is usually not necessary to maintain the visual benefit.


Diabetic Macular Edema NEWS

Below are current articles from a Google News Feed on Diabetic Macular Edema

This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Version of Event

Global Diabetic Macular Edema Drug Sales Market Size, Share ...
Digital Journal
Digital Journal is a digital media news network with thousands of Digital Journalists in 200 countries around the world. Join us!
Diabetic Macular Edema Drug Market Analysis 2018 By ...Version of Event

all 6 news articles »

MD Magazine

Ranibizumab Shows Improved Outcomes for Patients with Concurrent DME, Macular Nonperfusion
MD Magazine
According to the results of a recent post hoc analysis for the RIDE and RISE studies, participants who had diabetic macular edema (DME) and concurrent baseline macular nonperfusion (MNP) experienced improved outcomes when treated with ranibizumab.


Trends Desk (blog)

Global Diabetic Macular Edema Drug Market Report 2018 by Manufacturers, States, Type and Application, Forecast to ...
Trends Desk (blog)
The new research from Global QYResearch on Global Diabetic Macular Edema Drug MarketReport for 2018 intends to offer target audience with the fresh outlook on market and fill in the knowledge gaps with the help of processed information and opinions ...
Global Diabetic Macular Edema Market US$ 4000 Mn by 2027satPRnews (press release)

all 4 news articles »

MD Magazine

ICO Publishes New Guidelines for Diabetic Retinopathy
MD Magazine
While anti-vascular endothelial growth factor (VEGF) therapy is gaining popularity as the first-line option to manage diabetic retinopathy in high resource countries, its cost is prohibitive in many low-resource areas which still recommend conventional ...


CBC.ca

28 new drugs added to provincial formulary
CBC.ca
Islanders will now have coverage for anti-vascular endothelial growth factor (VEGF) drugs for three additional eye conditions including diabetic macular edema, macular edema due to retinal vein occlusion, and choroidal neovascularisation. The province ...


Diabetic Macular Edema Drug Sales Market Size, Status and Outlook Trends 2025
faircolumnist.com
Diabetic Macular Edema Drug Sales Market Report 2018 provides a unique tool for evaluating the Market, highlighting opportunities, and supporting strategic and tactical decision-making. This report recognizes that in this rapidly-evolving and ...

and more »

theperfectinvestor.com

Diabetic Macular Edema Drug Market Overview and Scope 2018 to 2025
The Newsman
This report provides detailed analysis of worldwide markets for Diabetic Macular Edema Drug from 2012-2017, and provides extensive market forecasts (2018-2023) by region/country and subsectors. It covers the volumes, prices, historical growth and ...
Future of Diabetic Macular Edema Drug Market including key players Novartis, Bayer, Allergan, Hoffman-La Rochetheperfectinvestor.com

all 5 news articles »

Clearside Biomedical Announces Positive Topline Results from Phase 2 Clinical Trial of CLS-TA Used with Eylea in ...
GlobeNewswire (press release)
... topline results from its Phase 2 clinical trial (“TYBEE”) evaluating suprachoroidal CLS-TA used with intravitreally administered EYLEA® (aflibercept) (“intravitreal Eylea”) in patients with diabetic macular edema (“DME”) over a 6-month evaluation ...


Global Diabetic Macular Edema Market Anticipated to Reach CAGR ...
satPRnews (press release)
According to a recent Future Market Insights publication titled “Radiotherapy Devices Market: Global Industry Analysis & Opportunity Assessment 2017 – 2027”, ...

and more »

Diabetic Macular Edema Treatment Market to Witness a Pronounce Growth During 2017 – 2025
satPRnews (press release)
Diabetic macular edema (DME) is characterized by accumulation of fluid in the macula – a part of retina responsible for vision. Accumulation may cause by leakage of plasma constituents into the surrounding, consequently leading to edema. Diabetic ...


The Newsman

Diabetic Macular Edema Market Share, Growth, Region Wise Analysis of Top Players, Growth rate, Application and ...
The Newsman
The Diabetic Macular Edema Market Research Report 2018 focal point on in-depth Diabetic Macular Edema market analysis and future prospects of Diabetic Macular Edema market. Pipeline therapeutics development coverage provides descriptive product ...
Global Juvenile Macular Degeneration Treatment Market Professional Survey Report 2018 - QuestaleQuestale

all 29 news articles »

Healio

Treatment of DME poses complex choices, strives to overcome limitations
Healio
Diabetic macular edema remains a major concern despite the availability of technology for potentially earlier diagnosis and better options for treatment. The 2016 WHO Global Report on Diabetes showed that 422 million adults currently live with diabetes ...


Financial Counselor

Diabetic Macular Edema Market 2018 Global Advancements- Scioderm Inc, Birken AG and Shire Plc
Financial Counselor
Global Diabetic Macular Edema market report serves an in-sight survey of the forecast trends based on the historical and current market situation. A comprehensive analysis of the market standard, geographical regions, market key vendors, Diabetic ...


Global Diabetic Macular Edema Market Research Report – Register a Hugh Growth In Healthcare Industry by 2022
Coherent Chronicle (press release) (blog)
Worldwide Market Reports added Latest Research Report titled “Global Diabetic Macular Edema Market Research Report” to its Large Report database. The study provides information on market trends and development, drivers, capacities, technologies, and ...

and more »

The Newsman

Diabetic Macular Edema Market Pipeline Therapeutics 2018 Drug Description, Target Finding, and Key Players
The Newsman
Diabetic Macular Edema Market Pipeline Review, tracks core statistics comprising key pipeline therapeutics and drug profiles with mechanism of action (MoA), route of administration (RoA), molecule type as well as Diabetic Macular Edema Market report ...


MD Magazine

NSAIDs May Reduce Incidence of Macular Edema Following Cataract Surgery
MD Magazine
... study in Egypt indicate that using prophylactic non-steroidal anti-inflammatory drugs (NSAIDs) pre- and post-cataract surgery may help reduce the severity and frequency of the development of cystoid macular edema (CME) in the eyes of diabetic patients.


IRIDEX Announces Approval of CYCLO G6™ Glaucoma Laser ...
Nasdaq
MOUNTAIN VIEW, Calif., June 19, 2018-- IRIDEX Corporation today announced the approval of its CYCLO G6™ Glaucoma Laser system by South Korea's.
IRIDEX Announces Approval of CYCLO G6™ Glaucoma Laser System in KoreaGlobeNewswire (press release)

all 6 news articles »

Non-infectious Macular Edema Treatment Market to Reach US$ 17200 Mn by 2026 - Persistence Market Research
PR Newswire (press release)
Diabetes related complications are one of the main causes of macular edema and there is a high rate of Diabetic Macular Edema (DME) in several countries across Europe. This makes the European market highly lucrative for manufacturers to introduce ...

and more »

Version of Event

Diabetic Macular Edema Drug Market Analysis 2018 By Requirements, Demands and Supply
Version of Event
Global Diabetic Macular Edema Drug Sales Market Professional Survey Report 2018 provides strategists, marketers and senior management with the critical information they need to assess the global Diabetic Macular Edema Drug Sales sector. The global ...


Diabetic Macular Edema Treatment Market Size, Share, Trends, Growth factors, Top Key Players, Competitive ...
Digital Journal
Diabetic macular edema is a leading cause of vision impairment among people. Macular edema occurs when the fluid and proteins start collecting on or under the macula of the eye thereby resulting in swelling leading to distorted vision. Diabetic macular ...


Business Wire

ThromboGenics Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-149, a plasma kallikrein inhibitor, for ...
GlobeNewswire (press release)
ThromboGenics' clinical pipeline consists of THR-317, a PlGF inhibitor, for the treatment of diabetic macular edema (DME), which is in an ongoing Phase 2 clinical study in combination Lucentis®, and THR-149, a plasma kallikrein inhibitor which is in a ...
Bicycle Therapeutics Announces Clinical Milestone & Expands Collaboration with ThromboGenicsBusiness Wire (press release)

all 2 news articles »

Bevacizumab used more frequently than ranibizumab for Medicare beneficiaries with DME
Healio
Medicare beneficiaries are more likely to receive bevacizumab instead of ranibizumab for the treatment of diabetic macular edema, according to a study. In a sample of Medicare beneficiaries from the Medicare Part B claims from 2010 to 2013, a greater ...


The Newsman

Diabetic Macular Edema Market Research Global Analysis into Type, Equipment, Growth Rate into Regions and ...
The Newsman
Diabetic Macular Edema Market 2018 report offers In-Depth Comprehensive Insight of the pipeline (being worked on) therapeutics situation and development prospects crosswise over Diabetic Macular Edema advancement. The report provides detailed ...


Incredible News 24

Global Diabetic Macular Edema Market 2018 Vendors- Birken AG, Shire Plc, Scioderm Inc
Incredible News 24
The Global Diabetic Macular Edema Market Report elaborates the complete details of latest industry trends and business circumstances to help the Diabetic Macular Edema market aspirants in making key business decisions. All the vital aspects of Diabetic ...


Ampio Pharmaceuticals Inc (AMPE) Market Research Analysis 2018 to 2025
Med News Ledger
The company offers products for the treatment of osteoarthritis of the knee and for the treatment of diabetic macular edema. Its products include low molecular weight fraction of human serum albumin and ultra-low dose of danazol. Ampio's ultra-low dose ...


Med News Ledger

Diabetic Macular Edema (DME) Market Pipeline Development Activities 2018
Med News Ledger
Diabetic Macular Edema (DME) – Competitive Landscape, Pipeline and Market Analysis, 2018, report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the ...

and more »

Diabetic macular edema drug sales market analysis with global forecast to 2025 made available by top research firm
WhaTech
Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Diabetic Macular Edema Drug Sales in these regions, from 2013 to 2025 (forecast), covering.


NICE to partially review Iluvien reimbursement guidance
Healio
The company said it would be a “significant improvement in reimbursement guidance” if the pseudophakic-only lens restriction was lifted and all patients with diabetic macular edema could be treated. “We welcome the decision to review the most up-to ...


IOP spikes more likely after treatment in certain patients
Healio
Mild to moderate IOP spikes were seen after multiple injections of Ozurdex for treatment of uveitis, diabetic macular edema and retinal vein occlusion, but frequency of IOP spikes above 30 mm Hg did not increase, according to a study. Researchers ...


Diabetic Retinopathy Market| GLOBAL INDUSTRY ANALYSIS AND FORECAST TO 2024
The Newsman
Laser surgery segment is anticipated to witness significant growth over the forecast period due to rising adoption of lasers in various healthcare settings for treatment of diabetic macular edema (DME). Technological advancements in laser treatment to ...

» Load more